KIT and Familial prostate cancer: Further, exogenous SCF treatment promotes expression of CD117 by prostate cancer cells, in addition to the stem cell factors Oct3/4 and Nanog, [17] indicating that a stem cell like phenotype may be induced by CD117 activation by SCF.